Wegovy and similar weight-loss drugs may not 'pay for themselves'

By Allison Bell

News January 14, 2026 at 11:36 AM

Share & Print

What You Need To Know

The researchers used employer health plan data from Merative for 2016 through 2023.
The researchers looked at the impact of GLP-1 agonist use over five years.
The weight-loss drugs had little impact on total claims.

More From HR Executive

NOT FOR REPRINT

© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.